Modelling the health benefits and economic implications of implanting dual-chamber vs. single-chamber ventricular pacemakers in the UK

Europace

Volumn 8, Issue 6, 2006, Pages 449-455

  Caro, Jaime ^a,c   Ward, Alexandra ^a   Moller, Jorgen ^b  

^a CARO RESEARCH INSTITUTE   (United States)

^b Caro Research Institute   (Sweden)

^c ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Cost effectiveness; Costs; Dual chamber pacemaker; UK

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGED; ARTICLE; ARTIFICIAL HEART PACEMAKER; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CHRONIC DISEASE; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART VENTRICLE PACING; HUMAN; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SIMULATION; SINUS NODE; SINUS NODE DISEASE; STROKE; SURVIVAL; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BRADYCARDIA; CROSS-OVER STUDIES; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PACEMAKER, ARTIFICIAL; POSTOPERATIVE COMPLICATIONS; PROSTHESIS FAILURE; QUALITY-ADJUSTED LIFE YEARS; REOPERATION; SURVIVAL ANALYSIS;

EID: 33745205822     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eul042     Document Type: Article

References (32)

1. National Pacemaker Database Annual Report 2002. Central Cardiac Audit Database. http://www.ccad.org.uk/ccadweb.nsf.
2. Peninsula Technology Assessment Group. The effectiveness and cost effectiveness of dual chamber pacemakers compared to single chamber pacemakers for bradycardia due to atrioventricular block or sick sinus syndrome: Systematic review and economic evaluation. Assessment Report for public consultation.pdf. http://www.nice.org.uk/pdf/DCP (27 May 2004).
3. Lamas GA, Lee KL, Sweeney MO et al. Mode selection trial in sinus-node dysfunction: Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med 2002;346:1854-62.
4. Kerr CR, Connolly SJ, Abdollah H et al. Canadian trial of physiological pacing: Effects of physiological pacing during long-term follow-up. Circulation 2004;109:357-62.
5. Thackray SD, Witte KK, Nikitin NP, Clark AL, Kaye GC, Cleland JG. The prevalence of heart failure and asymptomatic left ventricular systolic dysfunction in a typical regional pacemaker population. Eur Heart J 2003;24:1143-52.
6. Dretzke J, Toff W, Lip G, Raftery J, Fry-Smith A, Taylor R. Dual chamber versus single chamber ventricular pacemakers for sick sinus syndrome and atrioventricular block. Cochrane Database Syst Rev 2004; 2:CD003710.
7. Lamas GA, Orav EJ, Stambler BS, Ellenbogen KA, Sgarbossa EB, Huang SK, Marinchak RA, Estes NA III, Mitchell GF, Lieberman EH, Mangione CM, Goldman L. Quality of life and clinical outcomes in elderly patients treated with ventricular pacing as compared with dual-chamber pacing. Pacemaker Selection in the Elderly Investigators. N Engl J Med 1998;338:1097-104.
8. Newman D, Lau C, Tang AS et al. Effect of pacing mode on health-related quality of life in the Canadian Trial of Physiologic Pacing. Am Heart J 2003;145:430-7.
9. Ellenbogen KA, Stambler BS, Orav EJ et al. Clinical characteristics of patients intolerant to VVIR pacing. Am J Cardiol 2000;86:59-63.
10. Kelton WD, Sadowski RP, Sadowski DA. Simulation with ARENA, 3rd ed. Boston: McGraw-Hill; 2003.
11. Skanes AC, Krahn AD, Yee R et al. Progression to chronic atrial fibrillation after pacing. The Canadian Trial of Physiologic Pacing. CTOPP Investigators. J Am Coll Cardiol 2001;38:167-72.
12. Wang TJ, Massaro JM, Levy D et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The Framingham Heart Study. J Am Med Assoc 2003;290:1049-56.
13. Connolly SJ, Kerr CR, Gent M et al. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med 2000;342:1385-91.
14. Tang AS, Roberts RS, Kerr C et al. Relationship between pacemaker dependency and the effect of pacing mode on cardiovascular outcomes. Circulation 2001;103:3081-5.
15. Ellenbogen KA, Hellkamp AS, Wilkoff BL et al. Complications arising after implantation of DDD pacemakers: The MOST experience. Am J Cardiol 2003;92:740-1.
16. Hart RG, Halperin JL, Pearce LA et al. Lessons from the Stroke Prevention in Atrial Fibrillation Trials. Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med 2003;138:831-8.
17. http://www.statistics.gov.uk/STATBASE/tsdataset.asp?vlnk=7172&More=Y.
18. Department of Health. NHS Reference Costs 2002. http://www.doh.gov/nhsexe/refcosts/2002app1xls (17 October 2003).
19. Coumadin 5 mg 2003 http://admin.safescript.com/drugcgic.cgi/START.
20. National Institute for Clinical Excellence. Guidance for manufacturers and sponsors. London: National Institute for Clinical Excellence; 2001.
21. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: National Institute for Clinical Excellence; 2004.
22. Sutton R, Bourgeois I. Cost benefit analysis of single and dual chamber pacing for sick sinus syndrome and atrioventricular block: An economic sensitivity analysis of the literature. Eur Heart J 1996;17:574-82.
23. National Institute of Clinical Excellence. Dual chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block. Technology Appraisal 88, February 2005.
24. Newman D. Relationships between pacing mode and quality of life: evidence from randomized clinical trials. Card Electrophysiol Rev 2003; 7:401-5.
25. Tobin K, Stewart J, Westveer D, Frumin H. Acute complications of permanent pacemaker implantation: Their financial implication and relation to volume and operator experience. Am J Cardiol 2000;85:774-6.
26. Parsonnet V, Bernstein AD, Lindsay B. Pacemaker-implantation complication rates: An analysis of some contributing factors. J Am Coll Cardiol 1989;13:917-21.
27. Plummer CJ, McComb JM. Detection of atrial fibrillation by permanent pacemakers: Observations from the STOP AF Trial. Card Electrophysiol Rev 2003;7:333-40.
28. Glotzer TV, Hellkamp AS, Zimmerman J et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: Report of the Atrial Diagnostics Ancillary Study of the Mode Selection Trial (MOST). Circulation 2003;107:1614-9.
29. Waktare JE, Malik M. Holter, loop recorder, and event counter capabilities of implanted devices. Pacing Clin Electrophysiol 1997;20:2658-69.
30. Law AM, Kelton WD. Simulation Modeling and Analysis. Boston: McGraw-Hill; 2000.
31. Jun JB, Jacobson SH, Swisher JR. Application of discrete-event simulation in health care and clinics: A survey. J Oper Res Soc 1999;50:109-23.
32. Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005;23:323-32.